DSIP (Delta sleep peptide) — what it does, evidence, and safety

What it is

DSIP (delta sleep-inducing peptide) is a naturally occurring nine-amino-acid peptide studied for promoting deep, slow-wave sleep and buffering stress, which is how it got its name. First isolated from rabbit blood in the 1970s, it's sold in Western markets only as a research peptide, and it is not FDA-approved or approved as a drug in any major country. Human trials are mostly decades old and give mixed results, and after about 50 years of study its exact mechanism is still not well understood.

What the research found

DSIP (delta sleep-inducing peptide) has been studied mainly for sleep. Most human trials are from the 1980s–90s and are mixed — some reported improved sleep in chronic insomniacs, others found changes that were measurable but not clinically meaningful. After roughly 50 years of study its mechanism is still not well established, and it has never been approved for any use. The sleep and stress uses people pursue rest on this modest, aging, mixed evidence plus user reports.

Status and regulatory position

Not FDA approved for any indication. Not approved as a pharmaceutical drug in any major regulatory jurisdiction (FDA, EMA, MHRA). Research-community use only. DSIP — nominated as a bulk drug substance under the name Emideltide — was reviewed and voted on by FDA's Pharmacy Compounding Advisory Committee at its July 23–24, 2026 meeting (Emideltide taken up July 24) for possible inclusion on the Section 503A Bulks List, with separate votes on the free base and the acetate. FDA's own pre-meeting briefing document proposed that neither form be included. FDA has published no summary minutes, vote results, or determination from that meeting as of 2026-09-03, and a PCAC recommendation is advisory and non-binding, so 503A compounding is not permitted on that basis; Emideltide/DSIP does not appear on the 503A Bulks List. This concerns compounding eligibility, not drug approval. Prohibited in drug-tested sport at all times, under WADA S0. DSIP is not named on the 2026 WADA Prohibited List, and no S2-class anabolic, GH-axis or growth-factor activity is attributed to it — but not-named is not permitted. S0 catches any substance with no current approval for human therapeutic use from any governmental health authority, which describes DSIP.[⁸] Russia and several Eastern European countries have a more developed research and clinical literature than the US/Western Europe — DSIP has been studied at multiple Russian institutes since the 1980s, but none of that work has produced a US- or EU-approved indication.

Safety

DSIP is not FDA-approved, and its safety in humans has not been established in modern controlled trials. It is not named on the WADA Prohibited List as of the 2026 edition, but WADA's S0 category covers any substance with no regulatory approval anywhere for human use, so tested athletes should treat it as prohibited. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

Disclosures

⚠️ For research and educational purposes only. DSIP is not approved by the FDA as a pharmaceutical drug for any indication. Information in this entry is informational, not medical advice. Always confirm dose calculations with the in-app calculator and consult appropriate professional guidance before any protocol decisions.

⚠️ Precision matters at low doses. DSIP is dosed in micrograms per dose — typical research-community injectable doses ( per dose) at typical reconstitution concentrations produce small draws in the range on a U-100 syringe. At those draw sizes, even a one-unit error is a meaningful percentage of the dose (a one-unit error is ~33%; the same one-unit error is ~10%). Always verify draws against the in-app calculator and double-check the unit count on the syringe before injecting — most acutely at the smallest draws in your titration.

⚠️ The DSIP evidence base is modest, mostly older, and mixed. Most published human clinical trials of DSIP for sleep indications are from the 1980s and 1990s (predominantly the Schneider-Helmert group); results across studies are inconsistent, with some reporting clinically meaningful improvement in chronic insomniacs and others reporting statistically-detectable-but-not-clinically-meaningful changes.[¹][²][³] The compound has not received FDA, EMA, or MHRA approval for any indication despite roughly 50 years since discovery. Modern (post-2010) clinical work in Western literature is sparse; Russian and Eastern European research has continued more actively but the bulk of that literature is not indexed in PubMed and is harder to verify against canonical primary sources. Researchers should be explicit with themselves about the modest, mixed, and aging evidence base when interpreting subjective effects.

⚠️ Mechanism of action is not well-established. Despite roughly 50 years of research, DSIP's molecular mechanism remains incompletely characterized.[⁴] Multiple mechanisms have been proposed in the literature (modulation of GABAergic transmission, opioid-receptor interaction, antioxidant activity, hypothalamic-pituitary-adrenal axis modulation, stress-buffering effects), but no single mechanism has been definitively established as the primary driver of DSIP's sleep effects. The compound's name ("delta sleep-inducing peptide") reflects the original observation that infusion increased delta-frequency EEG activity in rabbits — but the mechanism by which this occurs in humans, and the relationship between EEG-delta effects and subjective sleep quality, are not fully resolved.

Quick reference

Common vial sizes (research peptide)	lyophilized vials are the most common research-peptide format; and vials also encountered. Branded pharmaceutical products do not exist in the US/EU.
Sequence	Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). Nine amino acids. Molecular weight 848.8 Da.
Frequency	Most commonly once daily, pre-bed (within 30–60 minutes of intended sleep onset). Some protocols use intermittent dosing (every other day, or 3–5 days per week).
Half-life	Short — IV plasma half-life reported at ~7 minutes in early human pharmacokinetic work.[⁴] However, observed behavioral and EEG effects persist substantially longer than the short plasma half-life suggests, implicating receptor-modulation or downstream signaling rather than direct concentration-dependent action.
Route	Subcutaneous (most common in research-community use). Intravenous in early clinical trials. Intranasal formulations have been explored in Russian research literature.
Onset of action	Subjective sleep effects typically reported within 30–90 minutes of subcutaneous injection in research-community reports. Some clinical trials report cumulative effects across multiple consecutive nights of use rather than acute single-night effects.[¹]

In depth

DSIP (delta sleep-inducing peptide) is an endogenous nonapeptide. The compound was isolated and characterized by the Swiss research group of Schoenenberger, Monnier, and colleagues across a series of papers spanning the 1970s; the canonical amino-acid analysis, sequence determination, and synthesis paper is Schoenenberger, Maier, Tobler, Wilson, and Monnier (1978), part XI of a serial-numbered "delta EEG (sleep)-inducing peptide" series in *Pflügers Archiv*.[⁶] The peptide was isolated from the cerebral venous blood of rabbits subjected to electrical stimulation of the intralaminar thalamic area to induce slow-wave sleep, then purified, sequenced, and synthesized for further study. The name refers to the original observation that intracerebroventricular infusion of the peptide increased delta-frequency EEG activity (the EEG signature of slow-wave sleep) in recipient animals.

Sequence and structure. DSIP is a linear nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (single-letter code WAGGDASGE). Molecular weight is approximately 848.8 Da. The peptide does not contain any disulfide bridges or post-translational modifications in its canonical form, which contributes to relatively short plasma stability — the IV plasma half-life has been reported at approximately 7 minutes in early human pharmacokinetic work.[⁴] Despite this short plasma half-life, behavioral and EEG effects of DSIP administration in animal and human studies persist substantially longer than concentration-dependent action would predict, suggesting that the compound's effects involve receptor-modulation, downstream signaling, or active metabolites rather than direct concentration-dependent activity.

Mechanism of action — multiple proposed, none definitively established. Despite approximately 50 years since the original isolation, DSIP's molecular mechanism remains incompletely characterized.[⁴] The literature describes multiple proposed mechanisms, including: modulation of GABAergic neurotransmission (the dominant inhibitory neurotransmitter system relevant to sleep); interaction with opioid-receptor signaling (some studies report DSIP attenuates opioid withdrawal symptoms in animal models, suggesting opioid-receptor crosstalk); antioxidant activity (DSIP appears to reduce oxidative stress markers in some preclinical models); hypothalamic-pituitary-adrenal (HPA) axis modulation (DSIP appears to attenuate cortisol responses to stress in some clinical and animal studies); and direct effects on hypothalamic sleep-promoting circuitry. No single mechanism has been definitively established as the primary driver, and the practical implication for researchers is that DSIP's effects across diverse indications (sleep, stress, withdrawal, antioxidant) may reflect either a single upstream mechanism with downstream pleiotropy or several distinct mechanisms operating in parallel.

Regulatory status. DSIP has never received FDA approval as a pharmaceutical drug for any indication. The compound has been studied clinically in multiple Western European countries (predominantly Switzerland and Germany) and in Russia/Eastern Europe, but no jurisdiction has approved it for therapeutic use. In the US, DSIP is sold as a research peptide by suppliers operating under research-chemical regulations. Its Section 503A compounding status was reviewed by FDA's advisory committee and no determination has issued (as of 2026-09-03). DSIP — nominated as a bulk drug substance under the name Emideltide (Emideltide free base / Emideltide acetate) — was on the agenda of FDA's Pharmacy Compounding Advisory Committee (PCAC) meeting of July 23–24, 2026, and the committee met on July 24 and voted separately on the free base and the acetate for possible inclusion on the Section 503A Bulks List. FDA published a briefing document evaluating the Emideltide/DSIP evidence base for the nominated uses of opioid withdrawal, chronic insomnia, and narcolepsy.[⁷] Those are the uses nominated and under FDA evaluation — not established efficacy, and the entry's framing of the evidence base (modest, older, mixed) is unchanged by the nomination. No outcome has been published: FDA has released no minutes or vote results from the meeting, the Committee's recommendation is advisory and non-binding in any case, and FDA had not issued a final determination as of 2026-09-03, so DSIP is neither confirmed on nor excluded from the final list. DSIP is also not a DEA-controlled substance — it appears in no schedule of the DEA's *Lists of Scheduling Actions, Controlled Substances, Regulated Chemicals*, August 2026 revision, searched in full on 2026-09-08 for "DSIP", "Delta sleep", "delta-sleep", "Delta Sleep-Inducing" and "WAGGDASGE" with zero matches.[⁹] DSIP is not listed in the WADA 2026 Prohibited List — direct text-search of the canonical 2026 WADA pdf (downloaded and archived at `docs/legal/wada-2026-prohibited-list.pdf` on 2026-05-04) returned no matches for "DSIP", "delta sleep", or "WAGGDASGE".[⁵] DSIP has no anabolic, GH-axis, or growth-factor activity, and would not be expected to fall under the WADA S2 categories that cover most peptide hormones.

Not named is not permitted — DSIP is prohibited at all times under S0. Falling outside S2 does not make DSIP allowed; it makes S0 the operative section, because S0 applies precisely to a substance "not addressed by any of the subsequent sections of the List". S0 reads, verbatim:

> Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

No jurisdiction has approved DSIP for therapeutic use — stated earlier in this same paragraph — so S0 captures it and it is prohibited at all times, in and out of competition.[⁸] A competitor reading only the zero-hit search result would draw the opposite conclusion, which is why the naming result and the S0 consequence are stated together here.

Researchers competing in WADA-tested sport should still confirm against the most recent annual Prohibited List edition before any competitive event — the WADA 2027 Prohibited List is expected to publish around September–October 2026 (effective 1 January 2027), and DSIP's status should be re-verified against that edition when it drops.

Common research interests. DSIP is one of the more long-tailed research peptides — it has been studied for multiple indications without producing approval for any of them. Common areas of research-community interest include: - Sleep, particularly chronic insomnia — the original and best-studied indication, with multiple human clinical trials from the 1980s and 1990s reporting mixed efficacy.[¹][²][³] - Stress and HPA-axis modulation — DSIP appears to attenuate cortisol responses to stress in some studies; this has been studied as a potential adjunct in chronic-stress and burnout protocols. - Opioid and alcohol withdrawal — Russian research literature describes DSIP use as an adjunct in withdrawal protocols, though the published Western primary literature on this is thin. - Antioxidant and "anti-aging" framing — DSIP appears to reduce oxidative stress markers in some preclinical models; this has been extrapolated into research-community "anti-aging" protocol use, though the human evidence base for this specific indication is essentially absent. - Stroke recovery (preclinical) — animal models have suggested potential neuroprotective and motor-recovery effects after focal stroke, but human clinical translation has not been established.

The diversity of proposed indications, combined with the absence of approval for any of them, is a useful signal of where DSIP sits in the evidence-quality landscape: a compound with a recognizable name and a long research history, but without the focused indication-specific evidence base that would support pharmaceutical development.

Reported side effects

Commonly reported

Injection site reactions (local redness, soreness, mild swelling) — uncommon but the most consistently reported adverse event
Vivid dreams or unusually intense dream recall — reported by some researchers, presumably reflecting changes in REM sleep architecture
Daytime grogginess or sluggishness — reported particularly with higher doses (>) or with use during the active daytime period rather than pre-bed
Mild headache — uncommon, typically transient
No consistent pattern of serious adverse events in research-community reports, though no controlled long-term safety surveillance exists
Schneider-Helmert and colleagues' studies of DSIP in chronic insomniacs reported the compound was "well tolerated" with no serious adverse events at the doses studied (typically 25 nmol/kg IV).[¹][²]
Some clinical trials reported transient mild side effects including dizziness, mild nausea, or warm sensations at the time of administration, particularly with IV dosing.
No deaths or persistent adverse outcomes have been reported in the published clinical literature.
HPA-axis effects with long-term use. DSIP appears to attenuate cortisol responses to stress in some studies; the long-term consequences of chronic HPA modulation in the research-community-use pattern (continuous or cycled daily use over months) have not been characterized.
Tolerance and dependence. No published clinical evidence demonstrates DSIP tolerance or dependence in humans; the absence of evidence is not evidence of absence, particularly given the absence of any long-term human safety surveillance.
Long-term safety in humans is essentially unknown. No multi-year human safety dataset exists for the modern research-community-use pattern (subcutaneous self-administration, often nightly, often in stack with other peptides).

Contraindications and warnings

Pregnancy and lactation: no data; default to contraindicated — no published reproductive toxicology in humans

Pediatric use: no data — should not be used in researchers under 18

Active sedative-hypnotic use — caution; theoretical risk of additive sedation though no published interaction data

Active opioid use — theoretical interest given DSIP's reported opioid-withdrawal-attenuation activity, but no published interaction data; researchers should not infer that DSIP can substitute for clinical opioid management

Severe sleep apnea, narcolepsy, or other primary sleep disorders — caution; DSIP has not been studied in these populations and any subjective sleep improvement could mask underlying pathology that warrants clinical evaluation

Active major depression or other primary mood disorder — caution; sleep modulation in the context of underlying mood disorders is a clinical question that should not be handled with research-community peptide protocols

Regulatory note (US): DSIP is sold as a research peptide and is not FDA-approved for any indication. Its Section 503A compounding status is under active FDA review — DSIP, nominated under the name Emideltide, is before the Pharmacy Compounding Advisory Committee at its July 23–24, 2026 meeting (DSIP discussed July 24) for possible inclusion on the 503A Bulks List, with an FDA briefing document evaluating the nominated uses of opioid withdrawal, chronic insomnia, and narcolepsy.[⁷] That meeting took place and the committee voted separately on Emideltide free base and Emideltide acetate; FDA's own briefing document proposed that neither be included. FDA has published no summary minutes, vote results, or final determination from that meeting as of 2026-09-03, and a PCAC recommendation is advisory and non-binding — panel review → FDA determination still pending → 503A compounding not permitted on that basis. Emideltide/DSIP is not on the 503A Bulks List. The nominated uses are uses under evaluation, not established efficacy. Researchers should track this docket and be aware of the regulatory environment in their jurisdiction.

Regulatory note (DEA): DSIP is not a DEA-controlled substance and appears in no schedule of the DEA's *Lists of Scheduling Actions, Controlled Substances, Regulated Chemicals* (August 2026 revision), checked 2026-09-08.[⁹]

Regulatory note (WADA): prohibited at all times under WADA S0. DSIP is not named in the 2026 List,[⁵] but S0 catches any substance with no approval for human therapeutic use anywhere — which DSIP lacks.[⁸] This may change in future annual editions; the 2027 list is expected around September–October 2026 (effective 1 January 2027), and researchers competing in WADA-tested sport should confirm against the most recent edition before any competitive event.

Key terms

Peptide: A short chain of amino acids, the building blocks of proteins. Many compounds in this library are peptides.
Half-life: Roughly how long the body takes to clear half of a dose. A long half-life is why some compounds can be taken only once a week.
Subcutaneous: An injection into the fatty layer just under the skin, rather than into a muscle or vein.
Mechanism of action: how a compound produces its effect in the body.

Sources

Related entries

CJC-1295 / Ipamorelin Blend — discussed together in this entry's stacks section
BPC-157 / TB-500 Blend — discussed together in this entry's stacks section
Adamax — same mechanism class
Cerebrolysin — same mechanism class
Oxytocin — same mechanism class
P021 — same mechanism class